188 related articles for article (PubMed ID: 8203856)
21. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
Moshkani SK; Dalimi A
Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
23. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.
Piketty C; Derouin F; Rouveix B; Pocidalo JJ
Antimicrob Agents Chemother; 1990 Aug; 34(8):1467-72. PubMed ID: 2221854
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.
Brun-Pascaud M; Chau F; Rajagopalan-Levasseur P; Derouin F; Girard PM
J Eukaryot Microbiol; 1996; 43(5):14S-15S. PubMed ID: 8822822
[No Abstract] [Full Text] [Related]
25. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.
Derouin F; Almadany R; Chau F; Rouveix B; Pocidalo JJ
Antimicrob Agents Chemother; 1992 May; 36(5):997-1001. PubMed ID: 1324642
[TBL] [Abstract][Full Text] [Related]
26. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Shubar HM; Lachenmaier S; Heimesaat MM; Lohman U; Mauludin R; Mueller RH; Fitzner R; Borner K; Liesenfeld O
J Drug Target; 2011 Feb; 19(2):114-24. PubMed ID: 20367080
[TBL] [Abstract][Full Text] [Related]
27. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW
Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
Araujo FG; Huskinson-Mark J; Gutteridge WE; Remington JS
Antimicrob Agents Chemother; 1992 Feb; 36(2):326-30. PubMed ID: 1605598
[TBL] [Abstract][Full Text] [Related]
29. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
Katlama C; Mouthon B; Gourdon D; Lapierre D; Rousseau F
AIDS; 1996 Sep; 10(10):1107-12. PubMed ID: 8874627
[TBL] [Abstract][Full Text] [Related]
30. Drug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome.
Winstanley P
Postgrad Med J; 1995 Jul; 71(837):404-8. PubMed ID: 7567731
[TBL] [Abstract][Full Text] [Related]
31. Two 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii.
Khan AA; Nasr M; Araujo FG
Antimicrob Agents Chemother; 1998 Sep; 42(9):2284-9. PubMed ID: 9736550
[TBL] [Abstract][Full Text] [Related]
32. Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
Araujo FG; Khan AA; Remington JS
Antimicrob Agents Chemother; 1996 Jun; 40(6):1335-7. PubMed ID: 8725996
[TBL] [Abstract][Full Text] [Related]
33. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
35. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.
Brun-Pascaud M; Chau F; Simonpoli AM; Girard PM; Derouin F; Pocidalo JJ
J Infect Dis; 1994 Sep; 170(3):653-8. PubMed ID: 8077724
[TBL] [Abstract][Full Text] [Related]
36. Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis.
Shiojiri D; Kinai E; Teruya K; Kikuchi Y; Oka S
Emerg Infect Dis; 2019 Apr; 25(4):841-843. PubMed ID: 30882331
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone].
Guelar A; Miró JM; Mallolas J; Zamora L; Cardenal C; Gatell JM; Soriano E
Enferm Infecc Microbiol Clin; 1994 Mar; 12(3):137-40. PubMed ID: 8011719
[TBL] [Abstract][Full Text] [Related]
38. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Romand S; Bryskier A; Moutot M; Derouin F
J Antimicrob Chemother; 1995 Jun; 35(6):821-32. PubMed ID: 7559193
[TBL] [Abstract][Full Text] [Related]
39. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Mahmoud MS
J Egypt Soc Parasitol; 1999; 29(3):791-803. PubMed ID: 12561919
[TBL] [Abstract][Full Text] [Related]
40. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo FG; Huskinson J; Remington JS
Antimicrob Agents Chemother; 1991 Feb; 35(2):293-9. PubMed ID: 2024964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
